Status:
COMPLETED
Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Actue Coronary Syndromes
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary purpose of the study was to evaluate 4000 subjects with acute coronary syndrome by comparing pravastatin 40 mg to atorvastatin 80 mg to determine if they are clinically equivalent, and to ...
Eligibility Criteria
Inclusion
- Hospitalization for MI or high risk unstable angina within the last 10 days.
- Total cholesterol 240 mg/dl or greater.
- Stabilized post ACS
Exclusion
- Co-morbidity with life expectations no more than 2 years.
- Current lipid lowering therapy
- Corrected QT interval
- Need for Class IA or III antiarrhythmic agent
Key Trial Info
Start Date :
November 1 2000
Trial Type :
INTERVENTIONAL
End Date :
December 1 2003
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT00382460
Start Date
November 1 2000
End Date
December 1 2003
Last Update
April 15 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.